Coalition of Doctors Condemns FDA Decision to Deny Women Access to Bioidentical Hormones

February 2008
Townsend Letter;Feb/Mar2008, Issue 295/296, p23
The article reports on the move of a coalition of doctors to condemn the decision of the U.S. Food and Drug Administration (FDA) to deny women to use bioidentical hormones. Accordingly, Bioidentical Hormone Initiative co-founder Erika Schwartz stated that the action of the FDA is a response to the petition filed by Wyeth Pharmaceuticals on the elimination of the use of estriol. In addition, Schwartz added that FDA is protecting the wealth of Wyeth rather than women's health and welfare.


Related Articles

  • FDA moves to highlight warnings about HRT. CMAJ // CMAJ: Canadian Medical Association Journal;3/18/2003, Vol. 168 Issue 6, p753 

    Reports that hormone replacement therapies prescribed in the U.S. must carry warnings that consumers will notice more easily. Introduction of the 'black box' warnings by the U.S. Food and Drug Administration after it reviewed data from the Women's Health Initiative Study; Plans for Health...

  • FDA Warns Against Menopausal Hormone Therapy.  // Life Extension;Feb2004, Vol. 10 Issue 2, p27 

    Reports on the nationwide campaign launched by the U.S. Food and Drug Administration on the risks and benefits of menopausal hormone therapy. Inclusion of hormone replacement therapies used by American women; Benefits from the therapy; Serious health concerns associated with the use of these...

  • Alternatives to T therapy: Lessons from male infertility. Hotaling, James M.; Brant, William O.; Kaplan, Steven A. // Urology Times;Nov2014, Vol. 42 Issue 12, p18 

    The article discusses the transition of testosterone prescriptions to alternative therapy to treat mal infertility in the U.S. It highlights the effort of the urologist to preserve the youthfulness of an aging baby boomer population and a younger population who seek treatment for infertility in...

  • Bioidentical Hormone Therapy. Files, Julia A.; Ko, Marcia G.; Pruthi, Sandhya // Mayo Clinic Proceedings;Jul2011, Vol. 86 Issue 7, p673 

    The change in hormonal milieu associated with perimenopause and menopause can lead to a variety of symptoms that can affect a woman's quality of life. Postmenopausal hormone therapy (HT) is an effective, well-tolerated treatment for these symptoms. However, combined HT consisting of conjugated...

  • FDA Refuses New Warnings on Estrogen for Tall Girls.  // Good Medicine;Spring/Summer2004, Vol. 13 Issue 2/3, p15 

    Reports on the refusal of the U.S. Food and Drug Administration to disallow the prescription of estrogens to suppress growth in tall girls as of March 2004.

  • Politics in Healing Enters Third Printing.  // Townsend Letter for Doctors & Patients;Jun2003, Issue 239, p141 

    Announces the third printing of the book 'Politics in Healing: The Suppression and Manipulation of American Medicine,' by former New York State assemblyman Dan Haley. Collection of successful case of alternative medicine; Criticism against the U.S. Food and Drug Administration for alleged bias...

  • No Fountain of Youth: FDA and HIH Review Off-Label Use of Hormones. Hanna, Kathi E. // Hastings Center Report;Jul/Aug2003, Vol. 33 Issue 4, p8 

    Discusses the results of a study on the effects of estrogen and progestin combinations on normal declines in cognitive functions when compared with placebo in women. Impact of a book written by gynecologist Robert Wilson on the use of estrogen; Conflicts in perceptions of the use of hormone...

  • Women's Health. Knutsen, Rebecca Mayer // Medical Marketing & Media;Sep2015, Vol. 50 Issue 9, p48 

    The article focuses on the innovation in women's health category, citing the return of the intrauterine device (IUD) and the development of a drug called female Viagra. Topics discussed include the approval of the U.S. Food and Drug Administration (FDA) for the marketing of the drug, the...

  • Back to nature. Snyder, Karyn // Drug Topics;11/18/96, Vol. 140 Issue 22, p42 

    Reports on the increasing awareness for the viability of alternative medicine by the US Food and Drug Administration (FDA). Recognition of the limitations on information availability on the field; Challenges presented in promoting the discipline; Implications of the FDA's renewed interest in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics